List of Fyarro drug patents

Fyarro is owned by Aadi.

Fyarro contains Sirolimus.

Fyarro has a total of 5 drug patents out of which 0 drug patents have expired.

Fyarro was authorised for market use on 22 November, 2021.

Fyarro is available in powder;intravenous dosage forms.

Fyarro can be used as treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) with a dose between about 56 mg/m2 and about 100 mg/m2 administered on days 1 and 8 of a 21-day cycle, treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma).

The generics of Fyarro are possible to be released after 28 October, 2040.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8911786 AADI Nanoparticle comprising rapamycin and albumin as anticancer agent
Feb, 2029

(6 years from now)

US10206887 AADI Prion free nanoparticle compositions and methods of making thereof
Apr, 2030

(7 years from now)

US10705070 AADI Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
Mar, 2036

(13 years from now)

US10973806 AADI Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin
Jun, 2036

(13 years from now)

US11497737 AADI NA
Oct, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Nov 22, 2024

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma); Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) with a dose between about 56 mg/m2 and about 100 mg/m2 administered on days 1 and 8 of a 21-day cycle

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic